Asset profile

Sacituzumab Tirumotecan

Antibody–drug conjugate

Phase 3underway

Evidence outlook · registrational

HR+/HER2- Metastatic Breast Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-12-31.

Also in development:Non-Small Cell Lung Cancer · Phase 3

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(47 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (8)

August 2026 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2026-08-31 · NCT07007780 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (1)

Phase 2Triple Negative Breast Cancer (TNBC), PD-L1 PositiveNot yet recruiting

Est. primary completion 2026-09-01 · NCT07153965 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (1)

Phase 2Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast CancerNot yet recruiting

Est. primary completion 2026-10-30 · NCT07054242 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (1)

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-11 · NCT06448312 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (4)

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-12 · NCT06711900 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2026-12-30 · NCT07108816 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-31 · NCT04152499 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2026-12-31 · NCT06081959 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (14)

February 2027 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-02-28 · NCT07438600 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-03 · NCT06992739 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (1)

Phase 1/2Triple Negative Breast CancerNot yet recruiting

Est. primary completion 2027-04-15 · NCT07139470 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-05 · NCT06670196 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-05-10 · NCT06074588 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (2)

Phase 2Lung CancerNot yet recruiting

Est. primary completion 2027-06 · NCT07244926 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-06-20 · NCT07343479 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (2)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-07 · NCT07071337 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-07-11 · NCT06312176 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-08-31 · NCT07329322 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-09 · NCT05445908 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-09-30 · NCT07703228 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)

Phase 2Lung CancerNot yet recruiting

Est. primary completion 2027-12-30 · NCT07197008 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Advanced Triple Negative Breast CancerNot yet recruiting

Est. primary completion 2027-12-31 · NCT06849492 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (15)

January 2028 (6)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-01 · NCT07670013 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-01 · NCT07109284 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2028-01-15 · NCT07466927 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-01-22 · NCT07548060 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-01-25 · NCT06170788 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2TNBC - Triple-Negative Breast Cancer, PD-L1 PositiveNot yet recruiting

Est. primary completion 2028-01-30 · NCT07244874 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2028 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-02-15 · NCT07545213 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-03-11 · NCT07471776 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-06-30 · NCT07375316 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (4)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-08 · NCT07371208 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Metastatic Triple Negative Breast CancersNot yet recruiting

Est. primary completion 2028-08 · NCT07458113 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-08 · NCT07697586 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2028-08-17 · NCT06305754 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)

Phase 2HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264, InetetamabRecruiting

Est. primary completion 2028-09-30 · NCT07182721 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-11-30 · NCT06706219 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (4)

January 2029 (1)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2029-01-12 · NCT06422143 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2029 (2)

Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2029-08-01 · NCT07738341 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Lung Neoplasm MalignantRecruiting

Est. primary completion 2029-08-17 · NCT07286149 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2029 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2029-09 · NCT07750704 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (2)

May 2030 (1)

Phase 3Triple Negative Breast NeoplasmsRecruiting

Est. primary completion 2030-05-18 · NCT06841354 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (1)

Phase 3Triple-Negative Breast CancerRecruiting

Est. primary completion 2030-12-16 · NCT06393374 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)

February 2032 (1)

Phase 2Lung Neoplasm MalignantRecruiting

Est. primary completion 2032-02-06 · NCT06788912 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (2)

January 2033 (1)

Phase 2Malignant NeoplasmRecruiting

Est. primary completion 2033-01-14 · NCT07252739 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2033 (1)

Phase 3Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast NeoplasmsRecruiting

Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2034 (1)

February 2034 (1)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2034-02-21 · NCT06312137 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.